3733-63-9
Chemical Structure
Decloxizine
Synonym(s): UCB-1402; NSC289116
- CAS No.: 3733-63-9
- Formula:C21H28N2O2
- Molecular Weight:340.46
IUPAC Name: 2-(2-(4-benzhydrylpiperazin-1-yl)ethoxy)ethan-1-ol
InChIKey: OXBBIHZWNDPBMQ-UHFFFAOYSA-N
SMILES: OCCOCCN1CCN(C(C2=CC=CC=C2)C3=CC=CC=C3)CC1
Biological Activity: Decloxizine (UCB-1402; NSC289116) is an orally active bronchodilator that can penetrate the blood-brain barrier. Decloxizine is a piperazine-type H1 histamine receptor antagonist. Decloxizine selectively blocks H1 histamine receptors, inhibiting histamine-induced capillary dilation, edema, and itching. Decloxizine has some 5-HT2 receptor antagonistic activity. Decloxizine can be used in studies of urticaria, allergic rhinitis, and bronchial asthma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Decloxizine | 99.80% | Decloxizine (UCB-1402; NSC289116) is an orally active bronchodilator that can penetrate the blood-brain barrier. Decloxizine is a piperazine-type H1 histamine receptor antagonist. Decloxizine selectively blocks H1 histamine receptors, inhibiting histamine-induced capillary dilation, edema, and itching. Decloxizine has some 5-HT2 receptor antagonistic activity. Decloxizine can be used in studies of urticaria, allergic rhinitis, and bronchial asthma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Decloxizine (Standard) | ≥98% | Decloxizine (UCB-1402; NSC289116) (Standard) is the analytical standard of Decloxizine. This product is intended for research and analytical applications.Decloxizine is an orally active bronchodilator that can penetrate the blood-brain barrier. Decloxizine is a piperazine-type H1 histamine receptor antagonist. Decloxizine selectively blocks H1 histamine receptors, inhibiting histamine-induced capillary dilation, edema, and itching. Decloxizine has some 5-HT2 receptor antagonistic activity. Decloxizine can be used in studies of urticaria, allergic rhinitis, and bronchial asthma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Daly MJ, Lightowler JE. Effect of decloxizine on histamine aerosol induced bronchoconstriction in the conscious guinea-pig. Arch Int Pharmacodyn Ther. 1969 Nov;182(1):215-8. [Content Brief]
- [2]. Kiehelä J, et al. Clinical investigation of a new broncholyticum--decloxizine--as compared with franol and placebo treatment. Respiration. 1970;27(6):582-90. [Content Brief]
- [3]. Scarpa GL. Effets de la décloxizine sur la symptomatologie clinique, la fonction respiratorie et la réaction cutanée à la sérotonine de sujets asthmatiques [Effects of decloxizine on clinical symptomatology, respiratory function and cutaneous reaction to serotonin in asthmatic patients]. Acta Tuberc Pneumol Belg. 1968 Jul-Oct;59(4):583-90. French. [Content Brief]
